Bloomberg News

Intercell Cuts Full-Year Sales, Earnings Forecast on Ixiaro

October 16, 2012

Intercell AG (ICLL) cut its forecast for full-year sales and earnings by as much as 20 percent, citing lower-than-expected demand for its Ixiaro vaccine against Japanese Encephalitis.

The net loss will be between 20 million euros ($26 million) and 24 million euros this year, the Vienna-based company said in statement today. Product sales will be between 26.5 million and 28.5 million euros, according to Intercell.

The company is scheduled to report third-quarter results on November 7.

To contact the reporter on this story: Eva von Schaper in Munich at

To contact the editor responsible for this story: Phil Serafino at

The Good Business Issue
blog comments powered by Disqus